Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells

Leukemia

Volumn 33, Issue 11, 2019, Pages 2695-2709

  Mishra, Ameet K ^a   Dingli, David ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MICRORNA 34A; POMALIDOMIDE; IL6R PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PHENFORMIN; SDC1 PROTEIN, HUMAN; SYNDECAN 1; THALIDOMIDE; TUMOR MARKER;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA SEQUENCE; SIGNAL TRANSDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IC50; METABOLISM; PATHOLOGY; PLASMA CELL; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; BORTEZOMIB; CELL LINE, TUMOR; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-6; METFORMIN; MULTIPLE MYELOMA; PHENFORMIN; PLASMA CELLS; RECEPTORS, INTERLEUKIN-6; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; SYNDECAN-1; THALIDOMIDE;

EID: 85064571834     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/s41375-019-0470-4     Document Type: Article

References (43)

1. Hirano T, Taga T, Yamasaki K, Matsuda T, Tang B, Muraguchi A, et al. A multifunctional cytokine (IL-6/BSF-2) and its receptor. Int Arch Allergy Appl Immunol. 1989;88:29–33.
2. Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci. 1985;82:5490–4.
3. Kishimoto T. INTERLEUKIN-6: From basic science to medicine—40 years in immunology. Annu Rev Immunol. 2004;23:1–21.
4. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295-a.
5. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014;10:720.
6. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63:1149–57.
7. Rose-John S. IL-6 Trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8:1237–47.
8. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA. 1993;90:3516–20.
9. Puthier D, Derenne S, Barillé S, Moreau P, Harousseau J-L, Bataille R, et al. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol. 1999;107:392–5.
10. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20.
11. Müller-Newen G. The cytokine receptor gp130: faithfully promiscuous. Sci STKE. 2003;2003:PE40.
12. Garbers C, Kuck F, Aparicio-Siegmund S, Konzak K, Kessenbrock M, Sommerfeld A, et al. Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR). Cell Cycle. 2013;12:3421–32.
13. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83.
14. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517.
15. Jelinek DF. Mechanisms of myeloma cell growth control. Hematol Oncol Clin North Am. 1999;13:1145–57.
16. Chou T-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res. 2010;70:440.
17. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.
18. Toyama EQ, Herzig S, Courchet J, Lewis TL, Losón OC, Hellberg K, et al. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Sci (New Y, NY). 2016;351:275–81.
19. Rokavec M, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Investig. 2014;124:1853–67.
20. Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, et al. Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms. Diabetes. 2015;64:1632–42.
21. Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang Y, et al. A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. Cancer Res. 2014;74:6236.
22. Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:26.
23. Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5:6-.
24. van der Aa MP, Elst MAJ, van de Garde EMW, van Mil EGAH, Knibbe CAJ, van der Vorst MMJ. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Amp; Diabetes. 2016;6:e228.
25. Wu L, Zhou B, Oshiro-Rapley N, Li M, Paulo JA, Webster CM. et al. An ancient, unified mechanism for metformin growth inhibition in C. elegans and cancer. Cell. 2016;167:1705–18.e13.
26. Singhal A, Jie L, Kumar P, Hong GS, Leow MK-S, Paleja B, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014;6:263ra159.
27. Rangarajan S, Bone NB, Zmijewska AA, Jiang S, Park DW, Bernard K, et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat Med. 2018;24:1121–7.
28. Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66:17–29.
29. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251–62.
30. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–73.
31. Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, et al. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25:463–71.
32. Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2012;52:381–400.
33. Truong DoM, Gyun Kim H, Ho Choi J, Gwang Jeong H. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic Biol Med. 2014;74:21–34.
34. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014;3:e02242–e.
35. McFarland-Mancini MM, Funk HM, Paluch AM, Zhou M, Giridhar PV, Mercer CA, et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol. 2010;184:7219.
36. Sommer JAN, Engelowski E, Baran P, Garbers C, Floss DM, Scheller J. Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis. Int J Mol Med. 2014;34:651–60.
37. Schuster B, Kovaleva M, Sun Y, Regenhard P, Matthews V, Grotzinger J, et al. Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem. 2003;278:9528–35.
38. Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, Hölscher C, et al. An Interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem. 2013;288:4346–54.
39. Lalau J-D. Lactic acidosis induced by metformin. Drug Saf. 2010;33:727–40.
40. Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60:1566–76.
41. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care. 1998;21:1659.
42. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care. 2004;27:1791.
43. Aharaz A, Pottegård A, Henriksen DP, Hallas J, Beck-Nielsen H, Lassen AT. Risk of lactic acidosis in type 2 diabetes patients using metformin: A case control study. PLOS ONE. 2018;13:e0196122.